The News

Rafaele Tordjman named Partner at Sofinnova Partners

13/12/2005

Paris, 13 December 2005 – Sofinnova Partners is pleased to announce that Rafaèle Tordjman has been promoted to Partner.

Rafaèle Tordjman, 36, joined Sofinnova Partners’ Life Sciences team as a research analyst in November 2001. Two years later she became an Investment Manager. At Sofinnova, she recently led a €4 million round of series A financing in Endotis Pharma, a French biopharmaceutical company in therapeutic glycoscience dedicated to drug discovery and development for cancer and inflammatory diseases.  Sofinnova Partners was the sole investor in this initial funding round. Rafaèle is a board member of Endotis Pharma and Endoart, a company developing vascular implants, as well as an observer at CoreValve, a company that has developed a proprietary delivery system for percutaneous aortic heart valve replacement based on a novel catheter and self-expanding approach on a beating heart. CoreValve received a €4.5 million financing from Sofinnova Partners in December 2003.

Prior to joining Sofinnova Partners, Rafaèle Tordjman was a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a Medical Doctor specialising in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialisation in haematology and internal medicine as a five-year fellow in Paris University Hospitals.

“We are delighted to welcome Rafaèle as Partner, which brings our total partnership to eight individuals,” said Jean-Bernard Schmidt, Managing Partner. “This well-earned promotion reflects the important contribution she has made to both the Life Sciences team and the partnership.”

For further information, please contact:

Madeleine Resener
Media Relations
Sofinnova Partners
Tel: +33 (0) 53 05 41 00 / +33 (0) 6 20 41 39 82
mresener@sofinnova.fr

About Sofinnova Partners
Founded in Paris in 1972, Sofinnova Partners is one of Europe's leading independent venture capital firms. With €900 million under management, Sofinnova Partners invests in start-ups and early-stage companies in information technology and life sciences. Its investment strategy consists of investing early in teams and projects with high potential, most often acting as lead or co-lead investor. Sofinnova Partners also benefits from a long-established relationship with its sister company in San Francisco, Sofinnova Ventures. Sofinnova Partners’ teams consist of 12 professionals who bring market insight and technical expertise to portfolio companies.